Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals

Tsuyoshi Fukumoto, Tatsuya Minami, Makoto Moriyama, Tomoharu Yamada, Taijiro Wake, Mizuki Nishibatake Kinoshita, Naoto Fujiwara, Ryo Nakagomi, Takuma Nakatsuka, Masaya Sato, Kenichiro Enooku, Hayato Nakagawa, Mitsuhiro Fujishiro, Shuichiro Shiina, Kazuhiko Koike, Ryosuke Tateishi – 30 May 2022 – The prognostic impact of direct‐acting antivirals (DAAs) on patients with hepatitis C‐related hepatocellular carcinoma (C‐HCC) is still unclear. This study aimed to evaluate the prognosis of C‐HCC in the DAA era.

Subscribe to